Prasad: #AACR18 Basket studies have some benefit, 'but mostly hype'. Next: NGS in relapsed /refractory tumors (F1CDX), covering 500K in US
6:39pm April 17th 2018 via Hootsuite
Prasad: #AACR18 Basket trials overall median resp rate is only 27%. But what would resp rate be from cytotoxics? 16.4-27.4% from 20y old Rx
6:38pm April 17th 2018 via Hootsuite
Prasad: #AACR18 Pt-level data, you can see over-rep sarcoma, salivary gland. Underrep: prostate and lung. Resp and non-resp: more non-resp
6:37pm April 17th 2018 via Hootsuite
Prasad: #AACR18 Tissue-agnostic basket studies - Hyman and Baselga, doing it right, and recognized (!) But to look at all baskets...
6:36pm April 17th 2018 via Hootsuite
Prasad: #AACR18 Onto basket studies: Larotrectinib in TRK Fusion-pos cancers - salivary-gland tumors, soft-tissue sarcomas, not so common
6:35pm April 17th 2018 via Hootsuite
Prasad: #AACR18 Adjuvant Rx eligable - still single-digit %'s.
Prasad: #AACR18 Total median duration of resp: 30 mos. Good drugs but not curative.
6:34pm April 17th 2018 via Hootsuite
Prasad: #AACR18 Shows FDA approved genome drugs: no exponential growth, no inflection point.
Prasad: #AACR18 Best-in-class, 54% median response rate. 95.1% of cancer pts who die do not benefit.
Prasad: #AACR18 Brand-new JAMA Oncol https://t.co/HJiXboqZeC 92% of cancer pts will die, not eligable assuming 100% market penetration
6:33pm April 17th 2018 via Hootsuite
Prasad: #AACR18 Some benefit; 'but mostly hype'. Genome-informed cancer medicine: FDA approved (ALK/criz); Basket studies (larotrectinib)
6:32pm April 17th 2018 via Hootsuite
Prasad: #AACR18 Hype defined; shows MDA graphic, large-scale profiling; and NYT "The Improvisational Oncologist" https://t.co/3PxwoeuFMN
6:31pm April 17th 2018 via Hootsuite
Vinay Prasad (OHSU OR) Is Genome-Informed Cancer Medicine Generating Patient Benefit or Just Hype? #AACR18 @VinayPrasadMD
6:29pm April 17th 2018 via Hootsuite
RT @Cait_Stewart: “Friendly”
6:28pm April 17th 2018 via Hootsuite
Hyman: #AACR18 Pts need knowledge. Need drug access and real-world evidence.
Hyman: #AACR18 NGS - can test for many mutation types; but cost; and tumor-only doesn't address germline. Clin trials alone insuff.
Hyman: #AACR18 Progress in small pt populations; prec med unlikely to be effective for a majority of cancer pts
6:27pm April 17th 2018 via Hootsuite
Hyman: #AACR18 How many pts do we help? ~15% routine biomarkers; +10% invest biomarkers; +10-15% speculative biomarkers, preclin support
6:26pm April 17th 2018 via Hootsuite
Hyman: #AACR18 Gives a few examples of enh cure rates through precision med - HER2+ Breast - Node+ still some benefit
6:25pm April 17th 2018 via Hootsuite
Hyman: #AACR18 Opening clinical trials to examine this possibility. Alt is to 'just treat everyone'. PARPi main in recurr, Pt-sens, Ov Ca
6:23pm April 17th 2018 via Hootsuite
Hyman: #AACR18 Germline alterations area also potential targets (BRCA1/2) - 2.7% of their population. 59% exhibit LOH in tumor - causative?
6:20pm April 17th 2018 via Hootsuite
Hyman: #AACR18 MSK-IMPACT can also give parallel germline Dx - pre-test counselling via video, 18% had results '17 https://t.co/fMZVvEPt1V
6:19pm April 17th 2018 via Hootsuite
Hyman: #AACR18 - tumor-agnostic Rx, Pembro in MSI-H solid tumors, ORR 40%. TRK Fusion+ :65% of pts had TRK freq <1%.
6:14pm April 17th 2018 via Hootsuite
Is Genome-Informed Cancer Medicine Generating Patient Benefit or Just Hype?Hyman: #AACR18 #PrecisionDecision Randomized controlled trials.
6:13pm April 17th 2018 via Hootsuite
Hyman: #AACR18 #PrecisionDecision But MSKCC is a referral center - underrepresented; their numbers are 'the floor'. https://t.co/hK7K4xaaWv
6:12pm April 17th 2018 via Hootsuite
Hyman: #AACR18 #PrecisionDecision Looking at MSK-IMPACT across 25K pt samples: 10% lvl1; 2% lvl 2A NCCN; 9% more lvl 3A clin trials.
6:10pm April 17th 2018 via Hootsuite
Hyman: #AACR18 What is a match? The continuum of evidence - Level 1 (FDA approved) Lev 2A, Lev 3A clinical trials #PrecisionDecision
6:09pm April 17th 2018 via Hootsuite
David Hyman (MSKCC NY): #AACR18 #PrecisionDecision Shows fig from '18 Nature https://t.co/AF7Iv6ZlaY The coplexity of ERBB2 mutations x type
6:08pm April 17th 2018 via Hootsuite
David Hyman: #AACR18 #PrecisionDecision https://t.co/CqfPp0dnaq
6:06pm April 17th 2018 via Hootsuite
Oncoceutics: #AACR18 Found that ONC201 crosses blood/brain barrier, thus candidate for anti-glioma Rx.
5:51pm April 17th 2018 via Hootsuite
Oncoceutics: #AACR18 ONC201 was ID'd as a p53-independent TRAIL-inducing compound in a phenotypic screen. https://t.co/9JPCHL3tQP
5:50pm April 17th 2018 via Hootsuite
Weingarten: #AACR18 Investors: BIO, AdvaMed, RESI, Life Sciences Summit, PMWC. Will facilitate presentations at investor events.
5:45pm April 17th 2018 via Hootsuite
Weingarten: #AACR18 Speakers from FDA, CMS, NSF, Pharma, Med-Tech, VCs, and NIH. 300 1:1 meetings with TRECS.
5:44pm April 17th 2018 via Hootsuite
Weingarten: #AACR18 GigaGen: raised $50M investment from Grifols, and launched product. TRECS (Transl. Resources to Enhance Comm. Success)
5:43pm April 17th 2018 via Hootsuite
Weingarten: #AACR18 Thus KinaSense went for preclin drug disc and will wait on oncology Dx later. And landed large service contract.
5:42pm April 17th 2018 via Hootsuite
Weingarten: #AACR18 100 teams have gone through I-Corps; experiential learning; instructors. Example: KinaSense tackling two markets
Weingarten: #AACR18 Has team of 14 (Ming Zhao program director of cancer diagnostics). Busy slide of 7 programs. I-Corps: entrepreneurship
5:39pm April 17th 2018 via Hootsuite
Weingarten: 16% imaging, 8% informatics. SBIR has central oversight, gives guidance, holds outreach, networking, funding #AACR18
5:36pm April 17th 2018 via Hootsuite
Weingarten: #AACR18 3 receipt dates: Sept 5, Jan 5, Apr 5. Signup https://t.co/RRkZ6X3Cu7 About 400 total projects; 35% Rx; 20% IVD
5:35pm April 17th 2018 via Hootsuite
Weingarten: #AACR18 Small Business Concern (SBC), for-profit, <500 empl, >50% US-owned. Could be >50% owned by VC, hedge funds, PE
5:31pm April 17th 2018 via Hootsuite
Weingarten: #AACR18 PhIIB is expecting recipients to have substantial 3rd party funds.
5:30pm April 17th 2018 via Hootsuite
Weingarten: PhIIB bridge award is for 'crossing the valley of death'; tech validation, clin translation. $4M over 3y #AACR18
5:29pm April 17th 2018 via Hootsuite
Weingarten: STTR - from academia to small business. 23 institutes at the NIH. SBIRs are in 3 ph:PhI is $300K 6-12mo. PhII is $2M 2y #AACR18
Weingarten: Small Business Innovation Research setup in 1982; a set 3.0% in FY16 of the NCI extramural budget. FY17 3.2% $982M #AACR18
5:27pm April 17th 2018 via Hootsuite
Michael Weingarten (NCI SBIR): Translating cancer technologies from lab to market: success stories from the NCI SBIR program #AACR18
5:25pm April 17th 2018 via Hootsuite
Smith: #AACR18 Majority of clonotypes from one pt - quad clone, FLT3/NRAS/WT1/DNMT3A. Evidence for allele dropout of DNMT3A <10% ("triple
4:29pm April 17th 2018 via Hootsuite
Smith: #AACR18 Studying mech of relapse: 11/25 pts - 5 were oncogenic NRAS. Able to show clonal evolution, confer resist to gilteritinib
4:25pm April 17th 2018 via Hootsuite
Smith: #AACR18 Her work '17 https://t.co/SNFDypSfcp Goes onto ASP2215 active in-vitro againts refractory FLT3 mutant AML OS still relapse
4:22pm April 17th 2018 via Hootsuite
Smith: #AACR18 Around 20% are ITD, point mutations are another 5-10%. FLT3 KD mutations D835V/Y/F are common resistance mechanisms
4:17pm April 17th 2018 via Hootsuite
Smith: FLT3 is the most common mutated gene in AML; a receptor TK. Most common are internal tandem duplications in juxtamemb domain #AACR18
4:16pm April 17th 2018 via Hootsuite
